Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
about
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationPractical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary careAtrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment optionsAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research instituteNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessSafety of new oral anticoagulant drugs: a perspectiveThe fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?Anticoagulation in atrial fibrillationExtra-pericardial tamponade following Wolf Mini-Maze procedure: a case report.Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyCerebral microbleeds: a review of clinical, genetic, and neuroimaging associations.New oral anticoagulants for atrial fibrillation: are they worth the risk?Personalizing oral anticoagulant treatment in patients with atrial fibrillation.A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.Novel oral anticoagulants in cardiovascular disease.Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.Newer clinically available antithrombotics and their antidotes.Direct oral anticoagulants: integration into clinical practice.Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes.Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?Why switch from warfarin to NOACs?Apixaban to prevent stroke in patients with atrial fibrillation: a review.Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.
P2860
Q26776413-68CF271A-F3B9-4956-B65C-C11A09E74E4EQ26785480-1EE39CEB-0B96-4020-A493-0A395DD0EC0FQ26799571-65718B91-D52B-4AAD-AA22-1FE2DBCEC3EEQ26851235-958AA075-74EF-4D26-8619-3E3234687CAAQ26863548-3D0B2A8A-6B44-48BD-9451-0BAAA490E388Q27016072-7896D7DE-D143-499F-898C-A9C2D6C04BC9Q28069442-94A83A57-3E60-4B03-9E15-8FE2BB33BFC1Q28077755-84DDD654-1D86-4E9B-82B0-27DFFC538A1AQ28315636-A69D320E-5ACD-4140-A623-D998C730A50CQ33166419-45F11606-8664-4BAD-A18E-94568411B9E4Q33897825-1B46338E-E441-4CF6-A716-572F99CFA510Q33924253-0F64969A-8B9C-432E-9F2C-7F6831E90D7FQ33924260-5CDFC1B5-2097-490B-9D7E-2CD79398627CQ34004770-1611E92D-CFB2-479D-ADEA-1AB647C1258EQ34109813-81BE7AEC-7B0A-492B-8120-07A1480304CAQ34297266-A0C8A84E-E199-4771-BE96-6DA95B828C06Q34658856-A96F2FB1-CE3C-44B1-94B2-9FE6C37285A8Q34967540-63D683B1-AEF5-4093-9486-7844CEADE7C0Q35629873-B78309C9-A302-4683-BBDD-24CE1D45C24AQ35689817-94D5D20D-6B65-47EE-9222-7BBD578BED75Q36030528-616F9C41-A452-4A41-8D4C-F4184A5D1D84Q37240690-5C374741-1583-4EF6-8BAC-D9FA24CEBDE7Q37435248-99265D25-7059-480F-94CE-CECDB608F993Q37641289-FC112E56-F7AB-4356-BF78-6F6D8BB7A369Q38129965-FB208CAC-18F6-4FF4-B981-AA37D8A1A86BQ38132927-6FD276BE-8A43-4C2F-A453-45486EAB8DB2Q38137852-25720C0C-DAF9-456A-BFD2-F40259D74FBDQ38183305-662F9BF1-5BAA-4CCF-BDDE-DD95ABB0AE1DQ38185977-FB30F2DA-F199-40D7-A8CB-C5B3C6F140C4Q38220693-926602D9-E8AB-47B4-8EDE-0A1C46ECBB9FQ38228212-7F761411-C367-4EDD-A553-CCAA52E9AC50Q38419246-EE197A3C-316D-4638-B9E4-3E1F853BBD9BQ38575711-299A7905-DF38-4690-B724-6B6CBB6D5F9AQ38588261-17E8AA0A-E546-49C0-A902-43DC4F6E8C89Q38658281-AF7427D6-C1BA-46D9-B829-8F87F9C378C4Q38728028-D201FD1B-8357-472B-9E12-1588562FFF19Q38773090-90F82B76-BDC6-4063-8FE1-1684657A071CQ38876376-1C0C3A1F-A9B0-48E5-AE31-41A4A74C94A6Q38878668-4A4060BE-3F70-4A9B-B3A7-53CA7FB2FBF9Q38900011-E234A2D0-A17F-41EB-9823-4BE120A0A340
P2860
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@en
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@nl
type
label
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@en
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@nl
prefLabel
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@en
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@nl
P2093
P50
P1433
P1476
Efficacy and safety of apixaba ...... ention in atrial fibrillation.
@en
P2093
Anne Hellkamp
Apixaban for Reduction in Stro ...... tion (ARISTOTLE) Investigators
Byung-Hee Oh
Denis Xavier
Dragos Vinereanu
Fernando Lanas
Jack Ansell
John Amerena
John D Horowitz
John H Alexander
P304
P356
10.1161/CIRCULATIONAHA.112.142158
P407
P50
P577
2013-05-02T00:00:00Z